A framework for identifying treatment-covariate interactions in individual participant data network meta-analysis. by Freeman, SC et al.
Freeman, SC; Fisher, D; Tierney, JF; Carpenter, JR (2018) A frame-
work for identifying treatment-covariate interactions in individual
participant data network meta-analysis. Research synthesis meth-
ods. ISSN 1759-2879 DOI: https://doi.org/10.1002/jrsm.1300
Downloaded from: http://researchonline.lshtm.ac.uk/4647712/
DOI: 10.1002/jrsm.1300
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
 This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/jrsm.1300 
 
This article is protected by copyright. All rights reserved. 
A framework for identifying treatment-covariate 
interactions in individual participant data network 
meta-analysis 
 
S. C. Freeman
(a, b)
, D. Fisher
(a)
, J. F. Tierney
(a)
, J. R. Carpenter
(a,c)
 
 
a. MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6NH, 
UK 
b. Department of Health Sciences, University of Leicester, University Road, Leicester, 
LE1 7RH, UK 
c. London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK  
Abstract 
Background: Stratified medicine seeks to identify patients most likely to respond to treatment. 
Individual participant data (IPD) network meta-analysis (NMA) models have greater power 
than individual trials to identify treatment-covariate interactions (TCI). TCI contain “within” 
and “across” trial interactions, where the across trial interaction is more susceptible to 
confounding and ecological bias.  
Methods: We considered a network of IPD from 37 trials (5922 patients) for cervical cancer 
(2394 events), where previous research identified disease stage as a potential interaction 
covariate. We compare two models for NMA with TCI: (i) two effects separating within and 
across trial interactions and (ii) a single effect combining within and across trial interactions. 
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We argue for a visual assessment of consistency of within and across trial interactions and 
consider more detailed aspects of interaction modelling, e.g. common vs trial-specific effects 
of the covariate. This leads us to propose a practical framework for IPD NMA with TCI.  
Results: Following our framework, there was no evidence in the cervical cancer network for a 
treatment-stage interaction based on the within trial interaction. The NMA provided additional 
power for an across trial interaction over and above the pairwise evidence. Following our 
proposed framework, the within and across trial interactions should not be combined.  
Conclusion: Across trial interactions are susceptible to confounding and ecological bias. It is 
important to separate the sources of evidence to check their consistency and identify which 
sources of evidence are driving the conclusion. Our framework provides practical guidance for 
researchers, reducing the risk of unduly optimistic interpretation of TCI.  
 
Keywords: Framework; IPD; Network meta-analysis; Treatment-covariate interaction.  
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1. Background 
Introduction 
Stratified medicine seeks to identify patients most likely to respond to treatment. However, 
individual trials are rarely powered to detect interactions between treatment effects and 
participant characteristics. Meta-analysis (MA) models potentially have greater power to 
identify such treatment-covariate interactions (TCI), particularly when individual participant 
data (IPD) are available. One of the big advantages of IPD MA over aggregate data (AD) MA 
is the greater power that it affords for investigating treatment and patient-level covariate 
interactions (Berlin et al., 2002; Debray et al., 2015; Lambert et al., 2002; Tierney et al., 2015). 
To explore how the treatment effect may vary in relation to a patient-level covariate, a TCI can 
be fitted (Donegan et al., 2012; Hua et al., 2017). The power to detect TCI will depend on the 
distribution of the covariate within each study (Simmonds and Higgins, 2007).  
Pairwise IPD MA of TCI often results in two sources of information; so-called ‘within trial’ (at 
the individual patient level) and ‘across trial’ (at the trial level) interactions, where the across 
trial interaction is particularly susceptible to confounding and ecological bias as it is based on 
observational associations  (Berlin et al., 2002; Debray et al., 2015; Hua et al., 2017; Riley et 
al., 2008; Riley and Steyerberg, 2010; Simmonds and Higgins, 2007; Thompson and Higgins, 
2005).The same is true of IPD network meta-analysis (NMA); therefore it is important that the 
within and across trial interaction estimates are reviewed separately, before deciding whether 
to combine them. We reiterate that confounding from unmeasured covariates (e.g. differences 
in baseline disease risk) can affect both within and across trial interactions (Jackson et al., 
2006). However, within trial effects are less susceptible because of the protection provided by 
the trials randomisation. Ecological bias arises if across trial information, which uses trial 
average covariate values, isused to draw conclusions about individuals (Greenland, 1987; 
Hong et al., 2015; Morgenstern, 1982; Simmonds and Higgins, 2007). However, if interest lies 
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in the population level effect and it is interpreted correctly as a population effect (and not an 
individual effect) then (by definition) there cannot be ecological bias. In some instances, it may 
be the case that the across trial interaction (e.g. the mean effect for a patient aged 50) truly 
differs from the within trial interaction (e.g. the effect for an individual patient aged 50) 
(Simmonds and Higgins, 2007). Separating out within and across trial interactions may change 
the conclusions drawn from combining within and across trial interactions. For example, an 
IPD MA comparing two anti-epileptic drugs as monotherapy for controlling seizures originally 
combined the within and across trial interactions and identified an interaction between 
treatment and age (Tudur Smith et al., 2005). However, a recent re-analysis separating out the 
within and across trial interactions no longer indicated an interaction between treatment and 
age based on the within trial interaction only (Hua et al., 2017).  
IPD MA models separating out within and across trial interactions were first developed for 
continuous outcomes (Riley et al., 2008) and later applied to time-to-event outcomes (Fisher et 
al., 2011). In the IPD NMA setting models separating out within and across trial interactions 
have been proposed for dichotomous outcomes (Donegan et al., 2012) and time-to-event 
outcomes using the Cox regression model (Hua et al., 2017). In this paper we show how to 
separate out the within and across trial interactions in the IPD NMA setting for time-to-event 
outcomes using the Royston-Parmar model.  
A key assumption of NMA is consistency between the direct and the indirect evidence (Salanti, 
2012; Dias et al., 2013). The inclusion of TCI in a NMA model offers one of many ways for 
exploring and understanding inconsistency (Cooper et al., 2009; Donegan et al., 2012, 
2013a,b). With the presence of TCI in a NMA model, the consistency assumption may be 
violated if one or more of the true treatment effects is modified by a covariate and included 
trials differ with respect to the covariate (Donegan et al., 2012). Furthermore, when we include 
TCI in a NMA model we assume that the treatment effects estimated at the covariate value of 
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zero are consistent and that the regression coefficients for the TCI parameters are also 
consistent (Donegan et al., 2017). Therefore, it is important to assess the consistency 
assumption either at each level of the covariate (for categorical covariates) or across a range of 
values (for continuous covariates) (Donegan et al., 2017).  
There are three different ways to model TCI effects: common, independent or exchangeable 
(Cooper et al., 2009). Common effects assume that the regression coefficients are the same for 
all TCI so that the TCI effect is the same for each treatment compared tothe control. 
Independent effects assume that all TCI are different for each treatment versus the control so 
that a separate regression coefficient for each TCI is included in the model. Exchangeable 
effects assume that all TCI are different from each other but similar enough that they can be 
sampled from a common distribution. For IPD MA, and as we show by extension in IPD NMA, 
there are three possible ways of analysing TCI: using the across trial interaction only, using the 
within trial interaction only and combining the two (Fisher et al., 2017). We now describe three 
approaches for IPD MA with TCI before considering the NMA setting.  
In one commonly used approach for interactions in MA (which can be shown to combine 
within and across trial interactions), specifically for categorical covariates, the treatment effect 
is calculated within each trial for each level of the covariate. The treatment effects for each 
level of the covariate are combined across all trials, using standard MA techniques, resulting in 
an overall effect for each level of the covariate which are then compared to each other (Fisher et 
al., 2011, 2017; Riley et al., 2008). Any trials where all patients have the same covariate value 
will not contribute to the within trial interaction but can contribute to the across trial 
interaction. This is a common approach used in IPD MA. However, the within trial interaction 
can be exaggerated or masked by the across trial interaction, which is at risk of ecological bias. 
Therefore, this approach is also at risk of ecological bias (Fisher et al., 2011, 2017; Riley et al., 
2008).  
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An analysis using the across trial interaction only considers how the treatment effect varies 
across trials in relation to the trial mean value of the covariate and fails to use the patient-level 
information (Thompson and Higgins, 2002). This requires the assumption of no unmeasured 
confounding between the outcome and the covariate, and that there is no ecological bias (Fisher 
et al., 2017; Riley et al., 2008; Riley and Steyerberg, 2010). Unfortunately it is typically not 
possible to identify such confounders as baseline data often varies across trials. Therefore it is 
often not possible to test whether the inclusion of the across trial interaction will induce bias.  
 
An analysis using the within trial interaction only more closely parallels the underlying 
principles of MA. Estimates of the TCI effect are calculated within each trial and then pooled 
together using MA methods (Simmonds and Higgins, 2007; Riley et al., 2008; Fisher et al., 
2011). Any trials where all patients have the same covariate value will not contribute to this 
analysis as they do not provide any within trial interactions (Fisher et al., 2017; Riley et al., 
2008; Simmonds and Higgins, 2007). Recommendations on the presentation and analysis of 
TCI using this approach are proposed by Fisher (2017). A key aim of this paper is to show how 
these recommendations can be brought to bear in NMA.  
In the pairwise MA case, it is clear that within trial interactions are the most clinically relevant 
estimates, as they are free from ecological bias (Berlin et al., 2002; Donegan et al., 2012; Fisher 
et al., 2017; Hua et al., 2017; Riley et al., 2008). In the NMA case, more research is needed to 
explore how the consistency assumptions of the network applied to within trial interactions (as 
in our model) can help to improve their precision. Nevertheless, the framework described here 
explicitly separates the within and across trial interactions throughout the network, and hence 
guarantees that an unbiased estimate of the within trial interaction is obtained. The methods 
proposed here are applicable to both continuous and categorical covariates. Specifically, in this 
paper we illustrate how the within and across trial interactions can be separated for 
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time-to-event outcomes modelled using the IPD Royston-Parmar NMA model, we propose a 
framework for conducting NMA with TCI, showing how to fit models which separate out the 
within and across trial interactions. We then illustrate our framework by applying it to a 
cervical cancer network.  
Why do we need a framework? 
Fitting a NMA with TCI is often a more complex process than researchers anticipate. There are 
a number of additional important decisions that need to be taken, beyond those that need to be 
considered in a MA. These include the parameterisation and consistency of covariate and 
interaction effects. An added complication, frequently encountered in practice, is how to 
handle missing patient-level covariate data.  
When it comes to reporting a NMA with TCI, the preferred reporting items for systematic 
reviews and meta-analyses based on IPD (PRISMA-IPD) guidelines recommend 
pre-specification of whether the across trial interaction is to be combined with the within trial 
interaction (Stewart et al., 2015; Tierney et al., 2015). Therefore, it is important that authors are 
aware of the potential implications of combining within and across trial interactions. By 
proposing a framework for conducting NMA with TCI we aim to equip researchers with the 
knowledge and tools for successfully fitting an appropriate NMA with TCI.  
In Section 2 we discuss issues to consider before conducting NMA with TCI, outline a 
nine-step framework for one-stage IPD NMA with TCI, provide guidance on implementing the 
framework and introduce a cervical cancer dataset. In Section3 we present the results of 
applying the framework to the cervical cancer network. In Section 4 we discuss the framework 
before drawing some conclusions in Section 5.  
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2. Methods 
Issues to consider 
Preliminary analysis 
NMA often starts with a systematic review being conducted to identify all treatments and trials 
to be considered in the network. As part of the review and in discussion with appropriate 
clinicians, discussion of any covariates which could be included in a NMA with TCI should 
take place before any models are fitted. Such models require a number of considerations and 
preliminary analysis of the data can help inform the decision of which model to fit.  
Common main effect vs trial-level main effect of covariate 
A patient-level covariate can be fitted as a common effect or a trial-level effect (Govan et al., 
2010). A common effect pools the effect of the covariate across all trials. A fixed trial effect 
results in a separate estimate of the effect of the covariate for each trial and does not provide an 
overall effect for the covariate. A random trial effect of a covariate allows the effect of the 
covariate to differ in each trial assuming that the coefficients for each trial come from a 
common (typically normal) distribution.  
We encourage the use of a trial-level effect, either fixed or random. If a common effect of a 
covariate is used when a trial-level effect would be more appropriate this can result in a poorly 
fitting model which could affect convergence, suppress the differences between trials and 
affect the treatment effect estimates. Assuming a common effect of a covariate is generally not 
appropriate when the distribution of the covariate varies between trials or in a network where 
trials vary in size, because it is known that smaller studies can give more extreme parameter 
estimates (Chaimani and Salanti, 2012). A hypothesis test to check the effect of the covariate in 
each trial should be conducted before assuming a common effect, as this choice is likely to 
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critically impact the estimate of the TCI.  
Parameterisation of within and across trial interactions 
TCI can be included in MA models in two ways. Firstly, as a single effect which combines 
within and across trial interactions; and secondly, as two effects which separate out the within 
and across trial interactions (Riley et al., 2008; Fisher et al., 2011). We now describe how to do 
this in the NMA setting using the Royston-Parmar model for time-to-event data.  
Consider the one-step fixed treatment effect Royston-Parmar NMA model for a network of 
𝑞 + 1 treatments (Freeman & Carpenter, 2017). Including a fixed trial effect of a patient-level 
covariate 𝑧𝑖𝑗 , the log cumulative hazard for patient i from trial j can be modelled as:   
 
      1ln | ln trt1 trtj ij j ij q ij j ijH t X s t a z      (1) 
where 𝑠𝑗 (ln ( 𝑡)) is the restricted cubic spline for trial j, trt1𝑖𝑗 ,… , trtq𝑖𝑗  are the treatment 
indicators with corresponding coefficients 𝛽1,… ,𝛽𝑞  and 𝛼𝑗  is the effect of the patient-level 
covariate 𝑧𝑖𝑗  for trial j.  
Adding a common TCI to (?) which separates the within and across trial interactions results in:  
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where the covariate 𝑧𝑖𝑗  is fitted as a fixed trial-level effect with coefficient 𝛼𝑗  for trial j and 𝑧 𝑗  
is the mean value of 𝑧𝑖𝑗  for trial j. The within trial interaction is represented by the 𝑎𝐴1,… , 𝛿𝐴𝑞  
parameters whilst the across trial interaction is represented by the 𝛿𝐵1,… , 𝛿𝐵𝑞  parameters. The 
difference 𝛿𝐵𝑘 − 𝛿𝐴𝑘  quantifies the amount of ecological bias for interaction k (Fisher et al., 
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2011).  
Adding a common TCI to (1) which combines the within and across trial interactions results in:  
 ln {𝐻𝑗 (𝑡|𝑥𝑖𝑗 )} = 𝑠𝑗 (ln ( 𝑡)) + 𝛽1trt1𝑖𝑗 + ⋯+ 𝛽𝑞 trtq𝑖𝑗 + 𝛼𝑗 𝑧𝑖𝑗  
                +𝛿1trt1𝑖𝑗 𝑧𝑖𝑗 + ⋯+ 𝛿𝑞 trtq𝑖𝑗 𝑧𝑖𝑗  (3) 
where the covariate 𝑧𝑖𝑗  is fitted as a fixed trial-level effect with coefficient 𝛼𝑗  for trial j and 
𝛿1,… , 𝛿𝑞  are the coefficients of the TCI effects.  
In practice, these models can also be fitted with random treatment effects, random trial-level 
treatment-covariate interactions and random trial-level effect of the covariate (Appendix A).  
Missing covariate data 
NMA can be conducted in both the frequentist and Bayesian frameworks (Lu and Ades, 2004; 
Lumley, 2002). One of the advantages of conducting NMA within a Bayesian framework, and 
in particular using WinBUGS, is that missing covariate data can be naturally handled in 
WinBUGS. Missing covariate data can be accommodated within the NMA model by including 
a distribution for the covariate with missing values. This allows two things to happen: missing 
covariate values are imputed which allows a patient to be included in the NMA model and this 
in turn increases the precision of the treatment effects which themselves inform the imputation 
of the missing values (Lunn et al., 2013). If we wish to perform a frequentist analysis, the most 
straightforward way to handle missing covariate values is by multiple imputation; however, 
this is not a straightforward application of multiple imputation, because the imputation needs to 
be done in a way that is consistent with the NMA model. The R-pacakge jomo (Quartagno and 
Carpenter, Stat Med, 2016) has the flexibility to handle this, but we do not pursue this further.  
Nine-step framework for one-stage IPD NMA with treatment-covariate interactions 
The aim of this framework is to provide guidance on the steps that need to be considered before 
a NMA with TCI can be fitted, so that the analysis is conducted systematically and 
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appropriately. This framework concentrates specifically on building NMA with TCI models. 
Therefore, the framework assumes that the usual MA activities such as protocol writing, 
defining inclusion/exclusion criteria and determining whether trials are similar enough for 
inclusion in a MA have already been conducted. Further, we assume that the network is 
connected and any covariates for inclusion in the NMA models have been identified through 
discussion with clinicians. As usual, when interpreting the results, a range of possible causes of 
heterogeneity (e.g. baseline differences, design, treatment doses, delivery, escape therapies) 
must be kept in mind. Steps 1-4 are applicable for any NMA whether covariates are considered 
for inclusion or not. From step 5 onwards the framework specifically considers the inclusion of 
covariates and TCI. This framework has been developed to be applicable to a range of 
outcomes (e.g. binary, continuous and time-to-event). As is common, we work on the log-odds 
or log-hazard scale. However, the principles underlying our proposed framework will apply to 
other settings but the technical details may vary. The framework may need to be tweaked to 
take into account additional issues arising in specific settings.  
1. Assess all pairwise treatment comparisons for evidence of heterogeneity  
(a) If heterogeneity is present, explore the baseline characteristics of all 
trials. Can the heterogeneity be explained by differences in baseline 
characteristics across trials?  
i. If yes, all important covariates should be considered going 
forwards  
ii. If no, it could be unsuitable to combine the pairwise comparison 
in a NMA  
2. Identify a reference treatment across the network and determine which 
treatment contrasts will be parameterised in the model (all other treatment contrasts 
should be obtained through consistency equations)  
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3. Fit the NMA model without covariates taking into account any heterogeneity 
identified in step 1 (e.g. by using a random effect model)  
4. Assess the network for evidence of inconsistency  
5. Investigate patterns of missing data for the covariate of interest  
6. Consider modelling assumptions for including the covariate in the NMA model 
(fixed or random treatment effects? common, fixed-trial or random-trial effect of 
covariate?)  
7. Fit NMA model including covariate and assess model results  
8. Fit NMA model including TCI with within and across trial interactions 
separated and assess agreement between the within and across trial interactions  
9. Fit NMA model including TCI with within and across trial interactions 
combined, if appropriate  
Note, when there is missing covariate data it is often practically and computationally easier to 
fit step 9 before step 8. More details can be found in the guidance on implementing the 
framework section.  
Guidance on implementing the framework 
Step 1: Before a NMA model is fitted all pairwise treatment comparisons in the network 
should be explored for evidence of heterogeneity. Heterogeneity can be assessed through the 
𝐼2, 𝜏2 and Cochran’s Q statistics (Cochran, 1954; Higgins et al., 2003; R¨ucker et al., 2008). If 
heterogeneity is present, explore the baseline characteristics of all trials. If one trial, or a 
subgroup of trials, are found to be causing the heterogeneity then exploring the baseline 
characteristics can identify what isdifferent about this trial, or trials, and the impact this might 
have on the treatment effect. The identification of heterogeneity, at this stage, in one or more 
pairwise comparisons can determine whether fixed treatment effect (FTE) or random treatment 
effect (RTE) models are used in step 4 (Mills et al., 2013). If the source of heterogeneity cannot 
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be identified or accounted for then either RTE will need to be used or it will be unsuitable to 
use this comparison in a NMA, particularly if removingthe pairwise comparison exhibiting 
heterogeneity means that a FTE model can be used. Any covariates identified, during this step, 
as potentially causing heterogeneity should be considered in steps 6 to 9.  
Step 2: The previous standard of care, the largest treatment node or the treatment connected to 
the greatest number of other treatments are the most appropriate choices for the reference 
treatment within the network. The treatment parameterisation of the network should satisfy the 
consistency equations (Higgins and Whitehead, 1996). The number of treatment parameters 
should be one less than the number of treatments in the network. The network diagram can help 
inform which treatment parameters should be directly estimated in the NMA model and which 
will be calculated as contrasts through the consistency equations. Network diagrams can be 
created in Stata  [52] using the networkplot command (Chaimani et al., 2013).  
Step 3: A NMA model can be fitted using both FTE and RTE and monitoring the deviance 
information criteria (DIC). If heterogeneity was present in step 2, the RTE model should be 
used as this increases the variability around the point estimate to reflect the heterogeneity. The 
RTE model gives more weight to smaller studies than the FTE model. Therefore, a difference 
in the treatment effect estimates between the FTE and RTE models can indicate publication 
bias and small study effects (Chaimani and Salanti, 2012). DIC is a measure of model fit which 
penalises model complexity - smaller values are better. DIC can be used to compare models 
although small differences (i.e. < 5) should not be over-interpreted and simpler models should 
be chosen where they can be (Spiegelhalter et al., 2002). In addition, in some cases, total 
residual deviance can be used to assess goodness of fit; see Dias (2013) for details.  
Step 4: The network should be assessed for evidence of inconsistency (Caldwell et al., 2005; 
Donegan et al., 2012, 2013b; Ioannidis, 2009; Lu and Ades, 2006; Salanti et al., 2007; Veroniki 
et al., 2013). To visualise this, it is useful to present the model results as a forestplot with the 
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network, direct and indirect evidence separated out. There are many approaches to assessing 
inconsistency (e.g. node-splitting (e.g. node-splitting (Dias et al., 2010; van Valkenhoef et al., 
2016; Tu, 2016), inconsistency models such as the design-by-treatment interactionmodel 
(Higgins et al., 2012; White et al., 2012), random inconsistency effects (Jackson et al., 2014, 
2016; Law et al., 2016), factorial analysis of variance (Piepho, 2014), generalised linear mixed 
models (Tu, 2015; Günhan et al., 2017)) and the two-stage approach (Lu et al., 2011)). We 
recommend consulting review papers such as Donegan et al (2013a) and Efthimiou et al (2016) 
which describe and compare different methods for assessing consistency to help select the most 
appropriate method for the network at hand.  
We use the inconsistency parameter approach of Lu & Ades (2006) in which an inconsistency 
parameter is fitted for each treatment loop and the model is re-fitted including the additional 
parameters. This approach complements the assessment of heterogeneity from step 1 and 
follows the approach outlined in Freeman & Carpenter (2017). Here an inconsistency 
parameter is initially added to the FTE model before considering the RTE model and exploring 
whether the conclusions are sensitive to the inclusion of the inconsistency parameter. If 
inconsistency is present in the network then an inconsistency parameter can be used in all 
further models. Treatment loops with inconsistency parameters are reduced to thedirect 
evidence only and therefore do not contribute to the across trial interaction in the network. 
Furthermore, if inconsistency is present, the cause of the underlying 
inconsistency/heterogeneity must be resolved before the results are used for clinical inference 
(Donegan et al., 2017; Freeman and Carpenter, 2017).  
Step 5: Consider the distribution of the covariate of interest in each trial. Are there any trials 
where some patients have missing covariate data? Are there any trials where all patients have 
missing covariate data? Is the covariate continuousor categorical? Can a linear effect between 
the groups of an ordered categorical covariate be assumed? What is the reference value of the 
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covariate? In WinBUGS (Lunn et al., 2000), as in all Bayesian modelling software, missing 
covariate data can be imputed once the marginal distribution of the covariate is specified.  
Step 6: Covariates can be included as common effects, fixed trial-level effects or random 
trial-level effects. DIC can be used to determine which of these assumptions is most 
appropriate. However, assuming a common effect of a covariate is only likely to be appropriate 
if the distribution of the covariate is the same in every trial in the network. The choice of FTE 
or RTE should be informed by previous steps such as the presence of heterogeneity from step 2 
or the DIC from step 4.  
Step 7: Fit the NMA models including the patient-level covariate and assess the results. This 
can help inform the decision of which NMA model with TCI to fit. TCI can be fitted as either 
common effects, fixed trial-level effects or random trial-level effects. A common effect 
assumes that the TCI has the same effect in all trials. A random trial-level effect allows the 
effect of the TCI to differ in each trial but assumes that the coefficients for each trial come from 
a common (typically normal) distribution. The choice of assumption for TCI can be informed 
by the distribution of the covariate within and across trials.  
Steps 8 & 9: The framework recommends that the within and across trial interactions are 
considered separately at first and then combined if it is appropriate to do so. However, the 
mean covariate value from each trial is needed to separate out the within and across trial 
interactions and to calculate this missing covariate data needs to be imputed. Although it is 
possible, in principle, to impute the missing covariate data, calculate the mean covariate value 
and fit the NMA model separating within and across trial interactions in one step, in practice 
software is unlikely do this. Therefore it is more practical and computationally easier to fit the 
model combining within and across trial interactions first and monitor the mean value of the 
covariate in any trials with missing covariate data before using these values to fit the model 
separating the within and across trial interactions. For trials with only some missing covariate 
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data the weighted average of the mean observed value and mean imputed value of the covariate 
can be used as the trial mean value. In trials where all patients have missing covariate values 
the mean covariate value from the imputed values can be used as the trial mean value. A 
sensitivity analysis in which patients with missing covariate data are excluded can be 
conducted to check the imputation of the missing covariate data has been handled correctly.  
A visual assessment of the agreement between the within and across trial interactions can be 
made by plotting the parameter estimates for the TCI. Log hazard ratios along with 95% 
credible intervals can be presented in tables. If TCI are present, the treatment effect parameters 
on their own do not have a useful interpretation. Treatment effects should be presented 
separately for each level of the covariate. Consistency can then be checked for each level of the 
covariate following methods described by Donegan et al (2017). Graphs ranking the treatments 
for each level of the covariate can be used as a visual aid for determining the most effective 
treatment for each level of the covariate (Chaimani et al., 2013; Salanti et al., 2011).  
Example 
Our example, comes from three meta-analyses of randomised controlled trials (RCTs) in 
cervical cancer performed by two international collaborations (Chemoradiotherapy for 
Cervical Cancer Meta-Analysis Collaboration, 2008; Neoadjuvant Chemotherapy for Cervical 
Cancer Meta-analysis Collaboration, 2003). The three meta-analyses considered four different 
treatments: radiotherapy (RT), chemoradiation (CTRT), neoadjuvant chemotherapy plus 
radiotherapy (CT+RT) and neoadjuvant chemotherapy plus surgery (CT+S) (Figure 1).  
The RT v CTRT comparison included a total of 18 RCTs and 4818 patients. In the original 
publication five of these trials were only included in sensitivity analyses as patients on at least 
one of the treatment arms received additional treatment. This resulted in a subset of 13 trials 
(3104 patients) which were identified and used for the primary analysis. Within this subset of 
13 trials one three-arm trial combined two different forms of CTRT and compared them with a 
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single control arm and three four-arm trials were split into two unconfounded comparisons of 
RT v CTRT for analysis as separate trials. This resulted in 16 trials included in the primary 
analysis. In this paper we will only consider the trials used in the primary analysis and will treat 
the data in the same way as the original publication (Chemoradiotherapy for Cervical Cancer 
Meta-Analysis Collaboration, 2008).  
Across the three meta-analyses that form our network of trials, overall survival data was 
available for 5922 patients from 37 RCTs (35 two-arm RCTs, 2 three-arm RCTs). Covariate 
data was available for stage of disease from 5517 patients from 36 RCTs.  
3. Results 
Application of framework to cervical cancer network 
In this section we illustrate the application of the proposed framework for one-stage IPD NMA 
with TCI to the cervical cancer network. In this example we use the one-stage IPD 
Royston-Parmar NMA model in the Bayesian setting to analyse overall survival (Freeman and 
Carpenter, 2017). Based on the availability of IPD stage of disease will be considered for 
inclusion in a NMA model with TCI. Based on a test of linearity we treat stage of disease as 
linear throughout the rest of this paper. All models were fitted in WinBUGS version 1.4.3 
(Lunn et al., 2000) and run with 20,000 burn-in and 20,000 iterations and two sets of initial 
values. Convergence was checked by examining the trace and histograms of the posterior 
distribution. Models were compared using the DIC statistic (Lunn et al., 2013; Spiegelhalter et 
al., 2002). Parameters representing the spline function for the baseline log cumulative hazard 
function, treatment effects and inconsistency parameters were fitted with non-informative 
normal prior distributions. In the random treatment effect (RTE) model the treatment effects 
were modelled using a multivariate normal distribution with the mean coming from a normal 
distribution and precision from a Wishart distribution. Parameter estimates are presented as log 
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hazard ratios (LogHR) and 95% credible intervals (CrI) for the posterior mean. A LogHR of 
zero indicates a null effect and a LogHR less than zero indicates a beneficial effect relative to 
the reference treatment, RT.  
Step 1: All pairwise treatment comparisons were assessed for evidence of heterogeneity using 
Cochran’s Q statistic and the 𝐼2 statistic (Cochran, 1954; Higgins et al., 2003). There was no 
evidence of heterogeneity within the RT v CTRT (p=0.625, Table 1) and CT+RT v CT+S 
(p=0.939) comparisons while there was some evidence of statistical heterogeneity in the RT v 
CT+S (p=0.065) comparison and substantial heterogeneity in the RT v CT+RT comparison 
(p<0.001, also noted in the original publication (Neoadjuvant Chemotherapy for Cervical 
Cancer Meta-analysis Collaboration, 2003)). The baseline characteristics of all trials were 
compared. A pre-specified analysis of RT v CT+RT identified a difference in treatment effect 
by chemotherapy cycle length. Therefore, CT+RT was split into two treatments based on the 
length of chemotherapy cycles. Throughout the rest of this paper trials with chemotherapy 
cycles less than or equal to 14 days will be referred to as ‘short cycles’ and trials with 
chemotherapy cycles greater than 14 days will be referred to as ‘long cycles’. No evidence of 
heterogeneity was found in the RT v CT+RT long cycles comparison (p=0.263). However, 
there was evidence of heterogeneity in the RT v CT+RT short cycles comparison (p=0.002). 
Heterogeneity can also be assessed visually from the forest plots in Figure 2. Treatment effects 
are presented in Table 1.  
We also assessed the assumption of proportional hazards (PH). Following the methods 
described by Freeman and Carpenter (2017), we performed a global test of non-proportionality 
which was not significant for any of the pairwise comparisons; therefore we continue under the 
assumption of PH in the cervical cancer network.  
Step 2: RT was chosen as the reference treatment because it was the previous standard of care. 
We included the RT v CTRT, RT v CT+RT and RT v CT+S treatment contrasts as parameters 
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in the NMA model resulting in the treatment effect for CT+RT v CT+S being estimated 
through the consistency equation.  
Step 3: A one-stage IPD Royston-Parmar NMA model was fitted to the cervical cancer 
network using both FTE and RTE with the results presented in Table 2. The DIC provides only 
weak evidence in favour of the RTE model (FTEDIC=12321.5, RTE DIC=12315.8). However, 
due to the presence of heterogeneity in the RT v CT+S short cycles comparison, identified in 
step 1, the RTE model was deemed to be the most appropriate model.  
Step 4: In Figure 3 the direct and indirect treatment effects differ from each other with the 
network estimates balancing out these two sources of information. The direct and indirect 
treatment effects are estimated through the inclusion of an inconsistency parameter which was 
estimated as -0.484 (95% CrI: -1.314, 0.354). Cochran’s Q statistic showed some evidence of 
inconsistency between designs (Q=10.32, 2 df, p=0.006). The inconsistency between designs is 
driven by one trial (Sardi et al., 1996) which had a treatment effect estimate more extreme than 
the other trials.  
In addition, we also assessed globally the assumption of proportional hazards across the 
network using the method recommended by Freeman and Carpenter (2017). The Wald test for 
non-PH from the RTE model with random treatment-ln(time)interactions gave 𝜒2 = 0.324 on 
3 degrees of freedom (p=0.955) giving no evidence of non-PH within the network.  
Step 5: A linear effect of stage of disease was assumed which could take the values 0 = stages 
1A-2A, 1 = stage 2B, 2 = stages 3A-4A. We assessed this assumption by conducting a Wald 
test for each trial which included patients covering all three categories of stage of disease. As 
each trial is independent, we summed together the chi-squared statistics to provide an overall 
test of the linearity assumption. This gave 𝜒2=8.19 on 12 degrees of freedom and p=0.77. 
Therefore, we proceeded withthe assumption of a linear effect for stage of disease.  
Thirteen trials had at least one patient with missing stage data. One of these trials had missing 
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stage data for all patients. To impute values of missing stage of disease (whether explicitly, 
using multiple imputation, or as part of a Bayesian model) we need to assume a distribution. 
We used a truncated normal distribution which we believe is a reasonable approximation for a 
clinical severity measure of this kind. This is especially so as (in common with other settings) 
the majority of information is recovered by bringing the observed data on patients with missing 
stage into the model, and not on the stage coefficients themselves. In WinBUGS, the normal 
distribution was truncated through the use of the ‘I’ function to restrict missing covariates to 
take values between 0 and 2. Results with a categorical stage model were similar, but we found 
it harder to obtain convergence  
Step 6: A common effect of stage of disease appeared to be inappropriate as the distribution of 
stage of disease varies across trials and the network includes trials of varying sizes. In addition, 
the DIC showed that a random effect of stage was most appropriate. Therefore, a RTE model 
with random trial-level effect of stage of disease was fitted.  
Step 7: As expected, when included as a covariate, the parameter estimate for stage of disease 
suggests that overall survival is reduced as stage of disease increases (LogHR=0.561, 95% CrI: 
0.475, 0.641; Table 2). Despite the inclusion of stage of disease as a covariate, the treatment 
effect for CTRT compared to RT remained statistically significant.  
Step 8: A RTE model with fixed trial-level effect of stage of disease and random trial-level 
effect of treatment-stage interactions separating out the within and across trial interactions was 
fitted. There were no statistically significant interactions between treatment and stage of 
disease (Table 3). The credible intervals for the RT v CT+S comparison are much wider, 
relative to the other treatment comparisons, possibly reflecting the small amount of within trial 
interaction. In this comparison, there are only two trials which have patients distributed over 
more than one value of stage and can therefore contribute to the within trial interaction.  
A visual assessment of the consistency of the within and across trial interactions was conducted 
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by plotting the parameter estimates for the treatment-stage interactions (Figure 4). To 
determine whether any information was gained from the NMA we also plotted the MA 
estimates from a FTE model (Figure 4). We used a relatively strict criterion considering 
agreement to be shown if the within trial interaction was within half a standard error of the 
across trial interaction.For the RT v CTRT comparison there is agreement between the within 
and across trial interactions. This is in line with our expectations as the RT v CTRT comparison 
was a branch of the network without any indirect evidence informing the comparison. 
However, in the case of RT v CT+RT and RT v CT+S the within and across trial interactions do 
not agree. For example, the LogHR of the within trial interaction for CT+RT is -0.035 (95% 
CrI: -0.285, 0.204) and the LogHR for the across trial interaction is 0.110 (95% CrI: -0.315, 
0.545; Table 3). The within and across trial interactions are not consistent with each other and 
the across trial interaction could be subject to ecological bias. Therefore we should focus on the 
within trial interaction only. For the RT v CT+RT and RT v CT+S comparisons further 
investigation into the difference between the within and across trial interactions may be 
required as these comparisons could be subject to ecological bias. 
Step 9: To fully illustrate our framework we also fitted a model combining the within and 
across trial interactions (Table 3). However, as mentioned in step 8, the within and across trial 
interactions should remain separated. Additionally, a sensitivity analysis in which patients with 
missing stage of disease were excluded was conducted (Table B.1, Appendix B). Table 3 and 
Table S.1 show good agreement between the two models. However, in Table S.1 the across 
trial interaction from the CT+S and stage interaction was statistically significant.  
4. Discussion 
NMA with TCI has the potential to identify groups of patients most likely to respond to 
treatment. We have proposed a practical framework which aims to encourage researchers to 
conduct one-stage IPD NMA with TCI in a systematic and appropriate manner. We have 
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successfully applied the framework to a cervical cancer network. The framework highlights the 
importance of preliminary analyses to consider issues such as heterogeneity and inconsistency 
which may inform decisions around the most appropriate modelling assumptions. This 
framework is deliberately generic, so that it can be applied to a range of outcomes (e.g. binary, 
continuous and time-to-event) and has the potential to improve the conduct and analysis of 
NMA with TCI.  
In the cervical cancer network we showed that stage of disease had a statistically significant 
effect on overall survival with advanced disease increasing the risk of death. Due to the 
presence of heterogeneity in the network a RTE model was considered to be the most 
appropriate. There was no evidence of a treatment-stage interaction based on the within trial 
interaction for any of the treatments leading to the conclusion that stage of disease did not 
modify the treatment effect. Based on our relatively strict criterion, the treatment-stage 
interaction models showed a difference between the within and across trial interactions for 
some of the comparisons and it was therefore most appropriate to separate out the within and 
across trial interactions. The small difference in the NMA and MA estimates of the across trial 
interaction suggested that some across trial interaction might have been gained from the 
network. Our criterion for assessing agreement between the within and across trial interactions 
is arguably somewhat strict and arbitrary. However, we feel it is better to be cautious as a 
number of treatment-covariate interactions identified in the literature have subsequently been 
debunked (Hua et al., 2017).  
The cervical cancer network is a small, well-connected network with a lot of direct evidence. 
Despite this we were still able to show that some across trial interaction is gained when 
conducting a NMA. Information (in the statistical sense of the inverse of the squared standard 
error) is gained in a NMA when the direct and indirect evidence are consistent. In practice, not 
all networks will contain as much direct evidence as the cervical cancer network. Therefore, we 
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would expect NMA to contribute agreater amount of statistical information on an across trial 
interaction in a consistent network where some treatment comparisons are only informed by a 
small amount of direct evidence. We may also expect to gain more information when using a 
fixed effects NMA.  
A reviewer suggested that (as the IPD data are available) the following simpler analysis may be 
preferable: (i) perform a two-stage MA of the within-study interaction effects, then (ii) derive 
the interaction effects within each study using the IPD and then perform NMA on these. In 
applications, this could provide a useful cross-check of the results. However, in our setting the 
network gives us the best treatment estimates against which to estimate an interaction. Further, 
NMA goes beyond just estimating treatment and interaction effects: a key motivation for NMA 
is to rank treatments in terms of efficacy. The inclusion of treatment-covariate interactions 
allows us to consider whether the ranking of treatments varies by covariate level. Indeed, if a 
treatment-covariate interaction is present, we should rank treatments for each level of the 
covariate.  
With the cervical cancer network we did not need to include an inconsistency parameter. 
However, in a network with one treatment loop if an inconsistency parameter is included then it 
may also be appropriate to allow for inconsistency in the TCI. This would be equivalent to 
conducting separate pairwise MA with TCI and nothing would be gained from conducting a 
NMA. We also only considered one covariate whereas in practice researchers may wish to 
consider multiple covariates. In this case, we would recommend considering each covariate on 
its own initially before combining any covariates identified as being clinically important within 
a NMA model.  
By definition, NMA uses both the within and across trial interactions. Using the across trial 
interaction requires the assumption of no unmeasured confounding, but unfortunately this 
assumption will always be hard to test. Making this assumption allows information to be 
  
This article is protected by copyright. All rights reserved. 
gained from the network to inform both treatment effect estimates and TCI. Each trial 
contributes to the within trial interaction which is estimated using patient-level covariates. 
Meanwhile the across trial interaction is estimated through the relation of the trial-level 
aggregated covariates (Hong et al., 2015). Although combining within and across trial 
interactions can result in greater power to detect TCI, the across trial interaction can introduce 
ecological bias (Lambert et al., 2002). It is therefore important that the within and across trial 
interactions for TCI can be separated out (Hua et al., 2017). Separating out the within and 
across trial interactions allows the influence of the across-trial interaction on the TCI to be 
assessed and allows researchers to identify which data source is driving the TCI.  
5. Conclusion 
NMA with TCI has the potential to identify groups of patients most likely to respond to 
treatment. To do this NMA requires the use of both within and across trial interactions. 
However, the across trial interaction can be subject to ecological bias. Therefore, it is important 
that the within and across trial interactions in a NMA can be separated and checked for 
agreement. We have shown that NMA models can be parameterised to separate out the within 
and across trial interactions. Our proposed framework incorporates the separation of within and 
across trial interactions, can be applied to any outcome, outlines the steps to conducting NMA 
with TCI in a systematic manner, provides practical guidance for researchers and reduces the 
risk of unduly optimistic interpretation of treatment-covariate interactions.  
Highlights 
What is already known?  
 Treatment-covariate interactions explore how a treatment effect varies in 
relation to a patient-level covariate.  
 Treatment-covariate interactions contain within and across trial interactions, 
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where the across trial interaction is susceptible to confounding and ecological bias.  
What is new?  
 We propose a nine-step framework for individual participant data network 
meta-analysis with treatment-covariate interactions  
 We use a cervical cancer example to show how to implement the framework, 
parameterise the network meta-analysis models to separate out the within and across 
trial interactions and assess the consistency of the within and across trial interactions.  
Potential impact for RSM readers outside the authorsâ€™ field  
 This framework provides practical guidance for researchers outlining the steps 
for conducting network meta-analysis with treatment-covariate interactions in a 
systematic manner reducing the risk of overly optimistic interpretation of 
treatment-covariate interactions.  
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Table 1. Cervical cancer meta-analysis results using Royston-Parmar models. FTE = 
fixed treatment effect. * Values are log hazard ratios and 95% credible intervals. 
 
Comparison  FTE*  Cochran’s Q  Global non-PH test   
RT v CTRT  -0.215  12.71, 15df,  𝜒2=0.161, 1df,   
 (-0.336, -0.086)  p=0.625  p=0.688   
RT v CT+RT  -0.191  20.69, 6df,  𝜒2=2.522, 1df,   
short cycles  (-0.375, -0.007)  p=0.002  p=0.112   
RT v CT+RT  0.227  12.34, 10df,  𝜒2=0.006, 1df,   
long cycles  (0.073, 0.385)  p=0.263  p=0.944   
RT v CT+S  -0.447  8.85, 4df,  𝜒2=0.118, 1df,   
 (-0.654, -0.243)  p=0.065  p=0.731   
CT+RT v CT+S  -0.444  0.01, 1df,  𝜒2=0.164, 1df,   
 (-0.830, -0.061)  p=0.939  p=0.686   
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Table 2. Posterior mean and 95% credible intervals for treatment effects from NMA 
models. FTE = fixed treatment effect, RTE = random treatment effect, RT = 
radiotherapy, CTRT = chemoradiation, CT+RT = neoadjuvant chemotherapy plus 
radiotherapy, CT+S = neoadjuvant chemotherapy plus surgery. *Stage is fitted as a 
random trial-level effect 
 
 FTE  RTE  RTE + Stage*  
CTRT  -0.211 (-0.337, -0.087)  -0.207 (-0.374, -0.046)  -0.198 (-0.346, -0.031)   
CT+RT short cycles  0.028 (-0.164, 0.220)  0.086 (-0.229, 0.428)  0.005 (-0.320, 0.328)   
CT+RT long cycles  0.223 (0.065, 0.380)  0.273 (0.031, 0.538)  0.254 (0.008, 0.540)   
CT+S  -0.396 (-0.611, -0.185)  -0.333 (-0.701, 0.011)  -0.372 (-0.803, 0.056)   
Stage    0.561 (0.475, 0.641)   
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Table 3. Posterior mean and 95% credible intervals for treatment and treatment-stage 
interaction effects from NMA models including treatment-stage interactions with within 
and across trial interactions separated and combined. Reference level is stages 1A-2A. 
RT = radiotherapy, CT+RT = neodadjuavnt chemotherapy plus radiotherapy, CT+S = 
neoadjuvant chemotherapy plus surgery. 
 
 Within & across trial 
interactions separated  
Within & across trial 
interactions combined   
RT v CTRT  -0.421 (-0.910, 0.101)  -0.428 (-0.738, -0.114)   
RT v CT+RT short cycles  -0.007 (-0.519, 0.550)  0.118 (-0.273, 0.596)   
RT v CT+RT long cycles  0.100 (-0.551, 0.670)  0.099 (-0.426, 0.613)   
RT v CT+S  0.332 (-0.593, 1.102)  -0.195 (-0.855, 0.380)   
RT v CTRT - stage within  0.176 (-0.069, 0.417)   
RT v CT+RT - stage within  -0.035 (-0.285, 0.204)   
RT v CT+S - stage within  0.172 (-0.459, 0.776)   
RT v CTRT - stage across  0.165 (-0.279, 0.584)   
RT v CT+RT - stage across  0.110 (-0.315, 0.545)   
RT v CT+S - stage across  -0.563 (-1.319, 0.230)   
RT v CTRT - stage combined   0.170 (-0.043, 0.373)   
RT v CT+RT - stage combined  0.006 (-0.234, 0.212)   
RT v CT+S - stage combined   -0.120 (-0.635, 0.415)   
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Figure 1: Cervical cancer network diagram. Node size is proportional to the number of patients 
randomised to each treatment and line thickness is proportional to the number of studies 
involved in each direct comparison. RT = radiotherapy, CTRT = chemoradiation, CT+RT = 
neoadjuvant chemotherapy plus radiotherapy, CT+S = neoadjuvant chemotherapy plus 
surgery. Note that this network diagram includes the main set of 13 RT v CTRT trials only 
(which in this paper is analysed as 16 trials due to the splitting of three four-arm trials each into 
two unconfounded comparisons of RT v CTRT), and the number of patients for each treatment 
arm does not add up to the total number of patients included in the network, because multi-arm 
patients are counted twice. There are a total of 37 trials in this network. However, in the figure 
the two multi-arm trials are counted three times each as they are included in the number of 
trials for each pairwise comparison. 
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Figure 2: Cervical cancer meta-analysis plots. Trial results come from a fixed treatment effect 
Royston-Parmar model. Overall results come from a one-stage IPD fixed treatment effect 
Royston-Parmar MA model. Top left: RT v CTRT, Top right: RT v CT+RT, Bottom left: RT v 
CT+S, Bottom right: CT+RT v CT+S. RT = radiotherapy, CTRT = chemoradiation, CT+RT = 
neoadjuvant chemotherapy plus radiotherapy, CT+S = neoadjuvant chemotherapy plus 
surgery, LogHR = log hazard ratio, CrI = credible interval. 
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Figure 3: NMA results for the cervical cancer network. Left = Fixed treatment effect, Right = 
Random treatment effect. RT = radiotherapy, CTRT = chemoradiation, CT+RT = neoadjuvant 
chemotherapy plus radiotherapy, CT+S = neoadjuvant chemotherapy plus surgery. 
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Figure 4: Treatment-stage interaction parameter estimates. Top: RT v CTRT, Middle: RT v 
CT+RT, Bottom: RT v CT+S. FTE = fixed treatment effect, RTE = random treatment effect, 
NMA = network meta-analysis, MA = meta-analysis. Solid lines represent NMA estimates. 
Dashed lines represent pairwise MA estimates. 
